Eroğlu Aydan, Sari Aliye
Department of General Surgery and Surgical Oncology, Numune State Hospital, Konya, Turkey.
Med Oncol. 2007;24(2):169-74. doi: 10.1007/BF02698036.
The published results on expression of c-kit in benign and malignant breast tissues vary.
The immunohistochemical expression of c-kit proto-oncogene product in 52 invasive breast cancer tissues and 16 benign breast tumor (fibroadenoma) tissues was studied using anti-c-kit proto-oncogene product antibody. Its expression was evaluated by immunoreactive score (IRS).
In breast cancer tissues, the mean IRS of c-kit proto-oncogene product expression was significantly increased compared to those of fibroadenoma (3.4 +/- 2 and 2.19 +/- 1.8, respectively,p = 0.035). The mean IRS of c-kit expression was higher in the group comprising estrogen (ER) positive tumor than in the group of ER negative (4.1 +/- 2.1 and 2.7 +/- 1.8, respectively,p = 0.012) but no statistically significant relationship was seen between the expression of c-kit proto-oncogene product and other clinicopathological parameters of breast cancer, including histologic type, tumor size, lymph node metastasis, distant metastasis, stage, progesterone receptor, c-erbB-2 expression, menopausal status and age of the patient (p > 0.05).
Our results show that a high level of c-kit expression occurs frequently in invasive breast cancer, and its expression is associated with ER but unrelated to other clinico-pathological variables.
关于c-kit在良性和恶性乳腺组织中的表达，已发表的结果各不相同。
使用抗c-kit原癌基因产物抗体研究52例浸润性乳腺癌组织和16例良性乳腺肿瘤（纤维腺瘤）组织中c-kit原癌基因产物的免疫组化表达。通过免疫反应评分（IRS）评估其表达。
在乳腺癌组织中，c-kit原癌基因产物表达的平均IRS显著高于纤维腺瘤（分别为3.4±２和2.19±1.8，p = 0.035）。c-kit表达的平均IRS在雌激素（ER）阳性肿瘤组高于ER阴性组（分别为4.1±2.1和2.7±1.8，p = 0.012），但c-kit原癌基因产物的表达与乳腺癌的其他临床病理参数，包括组织学类型、肿瘤大小、淋巴结转移、远处转移、分期、孕激素受体、c-erbB-2表达、绝经状态和患者年龄之间均无统计学显著关系（p＞0.05）。
我们的结果表明浸润性乳腺癌中经常出现高水平的c-kit表达，其表达与ER相关，但与其他临床病理变量无关。
